|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al Multicenter International Study of
Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of
Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil and
leucovorin as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar
|
|
3
|
Violette S, Poulain L, Dussaulx E, Pepin
D, Faussat AM, Chambaz J, Lacorte JM, Staedel C and Lesuffleur T:
Resistance of colon cancer cells to long-term 5-fluorouracil
exposure is correlated to the relative level of Bcl-2 and Bcl-X(L)
in addition to Bax and p53 status. Int J Cancer. 98:498–504. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cazin JL, Gosselin P, Cappelaere P, Robert
J and Demaille A: Drug resistance in oncology: From concepts to
applications. J Cancer Res Clin Oncol. 119:76–86. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eijdems EW, De Haas M, Coco-Martin JM,
Ottenheim CP, Zaman GJ, Dauwerse HG, Breuning MH, Twentyman PR,
Borst P and Baas F: Mechanisms of MRP over-expression in four human
lung-cancer cell lines and analysis of the MRP amplicon. Int J
Cancer. 60:676–684. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bailey-Dell KJ, Hassel B, Doyle LA and
Ross DD: Promoter characterization and genomic organization of the
human breast cancer resistance protein (ATP-binding cassette
transporter G2) gene. Biochim Biophys Acta. 1520:234–241. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Litman T, Brangi M, Hudson E, Fetsch P,
Abati A, Ross DD, Miyake K, Resau JH and Bates SE: The
multidrug-resistant phenotype associated with overexpression of the
new ABC half transporter, MXR (ABCG2). J Cell Sci. 113:2011–2021.
2000.
|
|
9
|
Xu J, Liu Y, Yang Y, Bates S and Zhang JT:
Characterization of oligomeric human half-ABC transporter
ATP-binding cassette G2. J Biol Chem. 279:19781–19789. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Turner JG, Gump JL, Zhang C, Cook JM,
Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS and
Sullivan DM: ABCG2 expression, function, and promoter methylation
in human multiple myeloma. Blood. 108:3881–3889. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
To KK, Zhan Z and Bates SE: Aberrant
promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell
Biol. 26:8572–8585. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
To KK, Zhan Z, Litman T and Bates SE:
Regulation of ABCG2 expression at the 3′ untranslated region of its
mRNA through modulation of transcript stability and protein
translation by a putative microRNA in the S1 colon cancer cell
line. Mol Cell Biol. 28:5147–5161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakano H, Nakamura Y, Soda H, Kamikatahira
M, Uchida K, Takasu M, Kitazaki T, Yamaguchi H, Nakatomi K,
Yanagihara K, et al: Methylation status of breast cancer resistance
protein detected by methylation-specific polymerase chain reaction
analysis is correlated inversely with its expression in
drug-resistant lung cancer cells. Cancer. 112:1122–1130. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mirza S, Sharma G, Pandya P and Ralhan R:
Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility
of breast cancer cells to anticancer agents. Mol Cell Biochem.
342:101–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Doyle LA, Yang W, Abruzzo LV, Krogmann T,
Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter
from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA.
95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Allen JD and Schinkel AH: Multidrug
resistance and pharmacological protection mediated by the breast
cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther. 1:427–434.
2002.PubMed/NCBI
|
|
17
|
Yoh K, Ishii G, Yokose T, Minegishi Y,
Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M and Ochiai A: Breast
cancer resistance protein impacts clinical outcome in
platinum-based chemotherapy for advanced non-small cell lung
cancer. Clin Cancer Res. 10:1691–1697. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
König SK, Herzog M, Theile D, Zembruski N,
Haefeli WE and Weiss J: Impact of drug transporters on cellular
resistance towards saquinavir and darunavir. J Antimicrob
Chemother. 65:2319–2328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Langmann T, Mauerer R, Zahn A, Moehle C,
Probst M, Stremmel W and Schmitz G: Real-time reverse
transcription-PCR expression profiling of the complete human
ATP-binding cassette transporter superfamily in various tissues.
Clin Chem. 49:230–238. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hendrich B and Bird A: Identification and
characterization of a family of mammalian methyl-CpG binding
proteins. Mol Cell Biol. 18:6538–6547. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Watt F and Molloy PL: Cytosine methylation
prevents binding to DNA of a HeLa cell transcription factor
required for optimal expression of the adenovirus major late
promoter. Genes Dev. 2:1136–1143. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perego P, De Cesare M, De Isabella P,
Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi
G, Pisano C, et al: A novel 7-modified camptothecin analog
overcomes breast cancer resistance protein-associated resistance in
a mitoxantrone-selected colon carcinoma cell line. Cancer Res.
61:6034–6037. 2001.PubMed/NCBI
|
|
23
|
Boyer J, McLean EG, Aroori S, Wilson P,
McCulla A, Carey PD, Longley DB and Johnston PG: Characterization
of p53 wild-type and null isogenic colorectal cancer cell lines
resistant to 5-fluorouracil, oxaliplatin and irinotecan. Clin
Cancer Res. 10:2158–2167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan J, Lv H, Peng B, Wang C, Yu Y and He
Z: Role of BCRP as a biomarker for predicting resistance to
5-fluorouracil in breast cancer. Cancer Chemother Pharmacol.
63:1103–1110. 2009. View Article : Google Scholar
|
